Welcome to our dedicated page for Sotera Health Co SEC filings (Ticker: SHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sotera Health Company's SEC filings document financial results, governance matters, capital-structure activity and material events for a Nasdaq-listed healthcare services company. Form 8-K filings report operating results, Regulation FD disclosures, earnings materials, leadership succession items, board appointments, committee assignments and underwriting agreements tied to secondary sales of common stock by selling stockholders.
Proxy materials describe annual meeting proposals, director elections, advisory executive compensation votes and auditor ratification. The filings also identify SHC's common stock, par value $0.01 per share, as listed on The Nasdaq Stock Market and provide formal exhibits such as underwriting agreements, legal opinions and press releases related to reported company events.
Sotera Health Co filed an initial insider ownership report for Kenneth D. Krause, who is identified as a director of the company. This Form 3 filing does not list any transactions or current holdings, serving mainly to register his status as a reporting insider under SEC rules.
Sotera Health Company announced a board transition. Constantine S. Mihas plans to resign as a Class I director effective March 16, 2026, and the company states his resignation is not due to any disagreement over operations, policies, or practices.
Effective the same date, the Board appointed Kenneth D. Krause as a Class I director. Krause is Executive Vice President and Chief Financial Officer of Rollins, Inc., with prior senior finance and strategy roles at MSA Safety. He will serve on Sotera Health’s Audit Committee and Litigation Committee, is deemed independent under Nasdaq rules, will enter into a customary indemnification agreement, and will receive standard non-employee director cash and restricted stock unit compensation under the company’s policy.
Sotera Health Co disclosed that investment funds affiliated with Warburg Pincus sold 15,000,000 shares of Sotera Health common stock on March 6, 2026 in an underwritten public secondary offering at $15.27 per share. After this transaction, the Warburg Pincus entities continue to indirectly hold a total of 19,102,952 shares through Bull Holdco L.P. and Bull Co-Invest L.P.
Warburg Pincus–affiliated entities reported a major share sale in Sotera Health Co. On March 6, 2026, certain Warburg Pincus Entities sold 15,000,000 shares of Sotera Health common stock in an underwritten public secondary offering at $15.27 per share. After this transaction, Warburg Pincus–affiliated vehicles reported indirect holdings of 19,102,952 shares, consisting of 15,287,717 shares held by Bull Holdco L.P. and 3,815,235 shares held by Bull Co-Invest L.P. Each Warburg Pincus entity disclaims beneficial ownership beyond its pecuniary interest.
Sotera Health Co ownership update: a group of Warburg Pincus entities reports an aggregate position of 31,838,253 shares of Common Stock, representing approximately 11.2% of outstanding shares. The filing states the percentage is calculated using 284,392,079 shares outstanding as of February 17, 2026.
The Warburg Pincus Reporting Persons say they are party to a Stockholders Agreement with GTCR and other holders; the GTCR Sponsors are publicly reported to own 12,735,301 shares per a Form 4 filed March 10, 2026. Each Warburg Pincus Reporting Person expressly disclaims beneficial ownership of shares held of record by the GTCR Sponsors except as set forth in the Stockholders Agreement.
GTCR Reporting Persons filed Amendment No. 6 to a Schedule 13G/A reporting shared voting power over 31,838,253 shares of Sotera Health Co. That amount represents approximately 11.2% of the 284,392,079 shares outstanding as of February 17, 2026, per the issuer's prospectus supplement.
The filing states the GTCR investors and the Warburg Pincus investors are party to a Stockholders Agreement covering governance and voting arrangements; the filing also notes that GTCR expressly disclaims beneficial ownership of shares owned of record by the Warburg Pincus investors. The filing is a joint disclosure by several GTCR entities, with signatures by Jeffrey Wright.
GTCR-affiliated funds associated with Sotera Health Co completed a large insider sale of Common Stock. On March 6, 2026, the GTCR XI Funds sold 10,000,000 shares of Sotera Health Common Stock in an underwritten public secondary offering at $15.27 per share.
After this transaction, the GTCR XI Funds collectively hold 12,735,301 shares, including 10,107,727 shares held by GTCR Fund XI/A LP, 2,546,564 shares held by GTCR Fund XI/C LP, and 81,010 shares held by GTCR Co-Invest XI LP. These holdings reflect a continued, but reduced, indirect ownership stake by the GTCR entities.
Sotera Health Company disclosed that certain existing stockholders entered into an underwriting agreement with Wells Fargo Securities, LLC to sell 25,000,000 shares of Sotera’s common stock. The shares were priced at $15.270 per share and were sold to the underwriter on March 6, 2026.
The company itself did not issue or sell any common stock in this transaction and will not receive any proceeds from the sale. None of Sotera Health’s executive officers took part as sellers in this offering. The filing also includes the full underwriting agreement and a related legal opinion as exhibits.
Sotera Health Company is registering 25,000,000 shares for resale by selling stockholders. The prospectus supplement states the underwriter has agreed to purchase the shares from the selling stockholders at $15.27 per share, which would yield $381,750,000 to those selling stockholders before expenses, and the Company will not receive proceeds from these sales.
The supplement lists delivery expected on March 6, 2026, notes a Nasdaq last reported sale price of $15.76 per share on March 4, 2026, and describes the underwriter’s ability to sell the shares on Nasdaq, OTC markets or through negotiated transactions.
Sotera Health Co Chairman & CEO Michael B. Petras Jr. reported multiple equity compensation transactions dated March 2, 2026. He exercised 89,686 performance-based share appreciation units (SAUs) granted in 2025 into the same number of common shares and received new awards of 240,248 restricted stock units (RSUs) and 120,124 SAUs under the 2020 Incentive Plan. Several blocks of common stock were withheld at $15.91 per share to cover tax liabilities upon vesting of earlier RSU and SAU awards, rather than sold in the open market. Following these transactions, he directly owned 692,427 common shares and indirectly held 4,819,393 shares through a grantor trust.